Table 3.
Multivariate logistic regression analysis to identify associated factors with baseline and monitoring examinations.
| Characteristics | Baseline | Monitoring | ||
|---|---|---|---|---|
| OR (95% CI) | P-value | OR (95% CI) | P-value | |
| Age (years) | 0.997 (0.995–0.999) | 0.005 | 0.989 (0.986–0.993) | < 0.001 |
| Sex | ||||
| Male | 1 (reference) | 1 (reference) | < 0.001 | |
| Female | 1.314 (1.209–1.428) | 1.346 (1.176–1.541) | ||
| Residence | ||||
| Metropolitan area/large cities | 1 (reference) | 0.004 | 1 (reference) | < 0.001 |
| Small cities/rural | 0.912 (0.857–0.971) | 0.657 (0.601–0.718) | ||
| Medical specialties prescribing HCQ | ||||
| Rheumatology | 1.074 (0.961–1.200) | < 0.001 | 1.185 (1.006–1.396) | < 0.001 |
| Dermatology | 1.522(1.281–1.807) | 0.994 (0.727–1.358) | ||
| Internal medicine other than rheumatology | 0.870 (0.766–0.988) | 0.845 (0.707–1.011) | ||
| Others | 1 (reference) | 1 (reference) | ||
| Hospitals of prescription | ||||
| Primary | 1 (reference) | < 0.001 | 1 (reference) | < 0.001 |
| Referral centers | 1.563 (1.407–1.736) | 2.312 (1.975–2.708) | ||
| Indications for HCQ use | ||||
| SLE | 1.713 (1.561–1.881) | < 0.001 | 1.349 (1.190–1.529) | < 0.001 |
| RA | 0.689 (0.634–0.748) | 0.570 (0.508–0.641) | ||
| Others | 1 (reference) | 1 (reference) | ||
| Mean duration (month) | 1.000 (0.998–1.002) | 0.892 | 1.017 (1.015–1.019) | < 0.001 |
| Mean daily dose (mg) | 0.998 (0.998–0.999) | < 0.001 | 0.998 (0.998–0.999) | < 0.001 |
OR odds ratio, CI confidence interval, HCQ hydroxychloroquine, SLE systemic lupus erythematosus, RA rheumatoid arthritis.